In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Patients with clinically confirmed infective endocarditis
Patients refuse to sign informed consent form
Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples
Patients with clinically confirmed infective endocarditis
Cohort
Other
Observational; No Interventions were given.
Other interventionObservational; No Interventions were given.
Change in the incidence of MACCE
MACCE is major adverse cardio-cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records.
Incidence of adverse thrombus complications
Adverse thrombus complications including systemic embolism, infected aneurysm, splenic abscess, etc.
Change in the incidence of infection recurrence
Diagnosis of infective endocarditis by clinical guidelines, which will be assessed from medical records.
Change in the incidence of myocardial infarction
Myocardial infarction, diagnosed by clinical doctors, will be assessed from medical records.
Change in the incidence of stroke
Stroke, diagnosed by clinical doctors, will be assessed from medical records.
Click on the lead sponsor to view all of their trials.
First Affiliated Hospital Xi'an Jiaotong University
Lead sponsor
521 Hospital of NORINCO Group
Collaborator
Shaanxi Provincial People's Hospital
Collaborator
Xiangyang Central Hospital
Collaborator
Henan Provincial People's Hospital
Collaborator
